SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Biolase, Inc – ‘8-K’ for 8/1/16 – ‘EX-99.3’

On:  Tuesday, 8/2/16, at 1:40pm ET   ·   For:  8/1/16   ·   Accession #:  1193125-16-668039   ·   File #:  1-36385

Previous ‘8-K’:  ‘8-K’ on / for 8/1/16   ·   Next:  ‘8-K’ on / for 8/8/16   ·   Latest:  ‘8-K’ on / for 4/19/24   ·   7 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 8/02/16  Biolase, Inc                      8-K:1,7,9   8/01/16    5:359K                                   RR Donnelley/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     25K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML    213K 
 3: EX-99.2     Miscellaneous Exhibit                               HTML      8K 
 4: EX-99.3     Miscellaneous Exhibit                               HTML     11K 
 5: EX-99.4     Miscellaneous Exhibit                               HTML     13K 


EX-99.3   —   Miscellaneous Exhibit


This exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  EX-99.3  

Exhibit 99.3

[BIOLASE, INC. LETTERHEAD]

August 1, 2016

Mr. Larry N. Feinberg

Oracle Partners, L.P.

Oracle Institutional Partners, L.P.

Oracle Ten Fund Master, L.P.

Oracle Associates, LLC

Oracle Investment Management, Inc.

200 Greenwich Avenue, 3rd Floor

Greenwich, Connecticut 06830

 

  Re: Amendment to Standstill Agreement

Ladies and Gentlemen:

Reference is made to that certain Standstill Agreement, dated November 10, 2015 (the “Standstill Agreement”), among Biolase, Inc. (“Biolase”), Mr. Larry N. Feinberg, Oracle Partners, L.P., Oracle Institutional Partners, L.P., Oracle Ten Fund Master, L.P., Oracle Associates, LLC and Oracle Investment Management, Inc.

In consideration for the willingness of Oracle Partners L.P. and Oracle Institutional Partners L.P. to provide capital to Biolase on the terms and conditions set forth in the securities purchase agreement, dated August 1, 2016 (the “Securities Purchase Agreement”), that Biolase expects to enter into immediately following the execution hereof, and subject to the closing of the transactions contemplated thereby in accordance with the terms thereof, Biolase hereby agrees to amend the Standstill Agreement such that the reference to “25%” therein is changed to “30%,” effective immediately prior to the closing of the transactions contemplated by the Securities Purchase Agreement. Except as described in the immediately preceding sentence, the Standstill Agreement shall remain in full force and effect.

This letter agreement shall be governed by, and construed in accordance with, the internal laws of the State of Delaware without giving any effect to principles of conflicts of laws.

[Signatures follow]


Sincerely,
BIOLASE, INC.
By:  

/s/ Harold C. Flynn, Jr.

Name:   Harold C. Flynn, Jr.
Title:   President and Chief Executive Officer

The foregoing is hereby accepted:

 

/s/ Larry N. Feinberg

LARRY N. FEINBERG
ORACLE PARTNERS, L.P.
  By: ORACLE ASSOCIATES, LLC, its general partner
    By:  

/s/ Larry N. Feinberg

      Larry N. Feinberg, Managing Member
ORACLE INSTITUTIONAL PARTNERS, L.P.
  By: ORACLE ASSOCIATES, LLC, its general partner
    By:  

/s/ Larry N. Feinberg

      Larry N. Feinberg, Managing Member
ORACLE TEN FUND MASTER, L.P.
  By: ORACLE ASSOCIATES, LLC, its general partner
    By:  

/s/ Larry N. Feinberg

      Larry N. Feinberg, Managing Member
ORACLE ASSOCIATES, LLC
  By:  

/s/ Larry N. Feinberg

    Larry N. Feinberg, Managing Member
ORACLE INVESTMENT MANAGEMENT, INC.
  By:  

/s/ Larry N. Feinberg

    Larry N. Feinberg, Managing Member

[Amendment to Standstill Agreement]


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on:8/2/16
For Period End:8/1/1610-Q,  8-K
11/10/158-K
 List all Filings 


7 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/10/21  Biolase, Inc.                     10-Q        9/30/21   84:13M                                    Donnelley … Solutions/FA
 8/13/21  Biolase, Inc.                     10-Q        6/30/21   80:12M                                    Donnelley … Solutions/FA
 5/13/21  Biolase, Inc.                     10-Q        3/31/21   81:9.4M                                   Donnelley … Solutions/FA
 3/31/21  Biolase, Inc.                     10-K       12/31/20   88:15M                                    ActiveDisclosure/FA
12/08/20  Biolase, Inc.                     S-1/A                  3:585K                                   Donnelley … Solutions/FA
11/13/20  Biolase, Inc.                     10-Q        9/30/20   81:11M                                    ActiveDisclosure/FA
 8/14/20  Biolase, Inc.                     10-Q        6/30/20   89:12M                                    ActiveDisclosure/FA
Top
Filing Submission 0001193125-16-668039   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sun., Apr. 28, 6:00:55.1am ET